Expert consensus on the off-label use in China of drugs for rare hematologic diseases (2024 edition)
Boxin Zhao, Xuan Zhou, Ping Zheng, Bo Zhang, Xiaoqin Feng, Jie Chen, Lisheng Cai, Yilu Chen, Liya He, Jianfen Su, Shuqin Cheng, Yingtong Zeng, Guowei Li, Bo Ji, Jianlong Wu, Weiyi Feng, Maobai Liu, Yiran Jin, Taotao Liu, Xiaolan Mo, Junyan Wu, Hui Wu, Hongliang Zhang, Zhichang Zheng, Zhihua Zheng, J · 2024
Read Expert consensus on the off-label use in China of drugs for rare hematologic diseases (2024 edition) by Boxin Zhao, Xuan Zhou, Ping Zheng, Bo Zhang, Xiaoqin Feng, Jie Chen, Lisheng Cai, Yilu Chen, Liya He, Jianfen Su, Shuqin Cheng, Yingtong Zeng, Guowei Li, Bo Ji, Jianlong Wu, Weiyi Feng, Maobai Liu, Yiran Jin, Taotao Liu, Xiaolan Mo, Junyan Wu, Hui Wu, Hongliang Zhang, Zhichang Zheng, Zhihua Zheng, J (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11621627.txt.
Description
Boxin Zhao and co-authors present an expert consensus from 2024 on off-label drug use for rare blood diseases in China. Drug package inserts guide safe prescribing, but they often lag behind care for rare diseases. Doctors then must use drugs outside their labels with thin legal cover. Experts of a Guangdong pharmacy group met to set a frame for such use. Their statement offers rules and a reference for clinics facing these choices.
Catalog record
| CREATOR | Boxin Zhao, Xuan Zhou, Ping Zheng, Bo Zhang, Xiaoqin Feng, Jie Chen, Lisheng Cai, Yilu Chen, Liya He, Jianfen Su, Shuqin Cheng, Yingtong Zeng, Guowei Li, Bo Ji, Jianlong Wu, Weiyi Feng, Maobai Liu, Yiran Jin, Taotao Liu, Xiaolan Mo, Junyan Wu, Hui Wu, Hongliang Zhang, Zhichang Zheng, Zhihua Zheng, J |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |